PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 23, 2026Journal of Crohn s and Colitis0 citations

Long-Term Effectiveness of Switching from IV to SC Infliximab in Inflammatory Bowel Diseases

P0867Long-term effectiveness, safety, acceptability, and progression of bowel damage of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases treated with intensified doses: The REMSWITCH-VLT study

View Full Paper

Authors

ABA BuissonMNM NachuryMBMaëva Bazoge

Discussion

Loading...

Member takes

Overview

Multicenter prospective study finds low relapse rates and high acceptability after switching infliximab delivery route in IBD patients, indicating safety and effectiveness.

Key Points

  • This study aims to evaluate the long-term effectiveness and safety of switching IBD patients from intravenous to subcutaneous infliximab.
  • Multicenter prospective design
  • Enrolled IBD patients in clinical remission on IV infliximab
  • Follow-up visits at specified intervals for monitoring outcomes
  • Collected data on relapse rates, acceptability, and bowel damage progression
  • 83.8% of patients recaptured clinical remission after dose escalation
  • Teraminal infliximab levels significantly increased post-switching
  • Only 2.2% of patients developed anti-infliximab antibodies
  • Endoscopic remission rates at 42 months were 72.9%
  • Acceptability score improved significantly, remaining stable over time
Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Buisson et al. (2026) studied this question.

synapsesocial.com/papers/69730ed4c8125b09b0d1e9f1https://doi.org/10.1093/ecco-jcc/jjaf231.1048
Ask AI
Helpful
Bookmark
Share
View Full Paper